Lenvima

Lenvima Indications/Uses

lenvatinib

Manufacturer:

Eisai

Distributor:

DKSH
Full Prescribing Info
Indications/Uses
LENVIMA is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).
LENVIMA is indicated in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.
LENVIMA is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy (see Pharmacology: Pharmacodynamics under Actions).
LENVIMA, in combination with pembrolizumab, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior platinum-based systemic therapy and are not candidates for curative surgery or radiation. This indication is approved based on tumor response rate and durability of response (see Pharmacology: Pharmacodynamics under Actions). Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in